Securities and Exchange Commission Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 1998 Biogen, Inc. (Exact name of Registrant as specified in its charter) Massachusetts 0-12042 04-3002117 (State or other (Commission (IRS Employer jurisdiction of File Number) Identification No.) incorporation) 14 Cambridge Center Cambridge, MA 02142 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (617) 679-2000 Item 9 Sale of Equity Securities Pursuant to Regulation S On March 27, 1998, the Registrant issued an aggregate of 3,350 shares of its Common Stock, $.01 par value per share, to thirteen employees of one of its European distributors of AVONEX (registered trademark) (Interferon Beta 1a)in connection with the achievement by the distributor of certain performance goals. The issuance of the shares was made in reliance on the provisions of Regulation S of the Securities Act of 1933. Each of the persons who received shares made a representation to the Registrant that he or she is not a "U.S. person" as defined under Rule 902 of Regulation S. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Biogen, Inc. By: /s/ Michael J. Astrue Michael J. Astrue Vice President - General Counsel Date: March 30, 1998